Form 4 for CTNM Contineum Therapeutics, Inc.
Accepted 2026-07-08 18:49:19 ET · period of report 2026-07-08 · accession 0001628280-26-047710 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-08 18:49 | 2026-07-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.01 | +2,500 | 19.7K | +15% | +$2,525 |
| DT | 2026-07-08 18:49 | 2026-07-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.00 | -2,500 | 17.2K | -13% | -$40.0K |
| DT | 2026-07-08 18:49 | 2026-07-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $0.00 | -2,500 | 279.4K | -0.9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-07-08 | M | A | 2,500 | $1.01 | 19,717 | D | — | — | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. |
| 2 | Common | Class A Common Stock | 2026-07-08 | S | D | 2,500 | $16.00 | 17,217 | D | — | — | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. |
| 3 | Derivative | Stock Option (right to buy) | 2026-07-08 | M | D | 2,500 | $0.00 | 279,430 | D | $1.01 · — to 2030-02-24 | 2,500 Class A Common Stock | (F1) These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. (F2) Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. |